Psoriasis susceptibility genes lce3d and tnip1 and their use

A technology for psoriasis and application, which is applied in the field of psoriasis susceptibility genes LCE3D and TNIP1 and the preparation of detection kits, to achieve the effect of rapid onset, high cure rate, and reduced liver toxicity

Active Publication Date: 2022-02-11
AFFILIATED HUSN HOSPITAL OF FUDAN UNIV
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Studies have found that gene polymorphisms of enzymes related to folic acid metabolism pathways are associated with the clinical efficacy and side effects of MTX in the treatment of rheumatoid arthritis: such as MTHFR1298A>C (rs1801131), ATIC347C>G (rs2372536), RFC-180G> A(rs1051266), SLC19A1A>G(rs2838956) and SLC19A1G>A(rs7499) are associated with the clinical efficacy of MTX; while RFC-180G>A(rs1051266) polymorphisms are associated with the toxicity of MTX, and the disease susceptibility loci There is little research attention on the relationship between the point and the clinical efficacy and side effects of MTX

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Psoriasis susceptibility genes lce3d and tnip1 and their use
  • Psoriasis susceptibility genes lce3d and tnip1 and their use
  • Psoriasis susceptibility genes lce3d and tnip1 and their use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Example 1: MTX Intervention Treatment of Clinical Effect of Temperature of Psoriasis and Deputy Observing Experiment

[0023] Materials and Methods:

[0024] 1) Psoriasis patients: Choosing January 2015 to June 2017 to psoriasis patients with skin cocibo chillophane diseases in Huashan Hospital in Huashan Hospital for observation.

[0025] 2) Medicine intervention method: Treatment 1 week and 2nd week a single oral oral MTX7.5mg, sections 3 weeks to the 4th week a week oral oral oral oral oral oral oral oral oral oral orally weekly per week.

[0026] 3) Incorporate the standard

[0027] (1) Age 18-60 years old;

[0028] (2) Patients with common type, joint disease, red skin disease and pustain psoriasis, body surface accumulated area (BSA)> 10% or gum area and severity index (PASI)> 10;

[0029] (3) Fill in the complete epidemiological questionnaire, signed an informed consent book.

[0030] 4) Exclude standard

[0031] (1) Other special types of ordinary psoriasis patients...

Embodiment 2

[0041] Example 2 Relevance between psoriasis susceptibility gene and MTX clinical efficacy

[0042] Materials and Methods: Extract the patient DNA, using the SEQUENM platform for genetic classification of 18 non-HLA sites of 90 patients, and whether the PASI75 is defined as a valid group and invalid group, and the results showed that The LCE3D genotype has statistically significant in the effective group and the invalid group;

[0043] (1) Comparison of patients with MTX therapy for effective groups and invalid group

[0044] The treatment of the PASI75 improved by MTX treatment was set as a valid group, and the remaining group is set to invalid group, and the effective group course (19 ± 12) significantly longer than the invalid group (14 ± 11), the difference is statistically significant P <0.05; lce3dsnp site RS4112788AG The probability of genotypes is significantly higher than that (31%) of the effective group (31%), and the difference is statistically p <0.05 (shown in Table ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of biotechnology, and relates to psoriasis susceptibility genes and their uses, in particular to psoriasis susceptibility genes LCE3D and TNIP1 and their use in the preparation of detection kits. The invention provides a new method for predicting the clinical efficacy of MTX The gene markers, especially the rs4112788AG genotype of the LCE3D SNP site and the rs10036748TT genotype of the TNIP1 SNP site can be used as gene markers to predict the clinical efficacy and side effects of MTX intervention in the treatment of psoriasis; the invention also provides a detection kit, The kit predicts the clinical efficacy and side effects of MTX by detecting the SNP sites of the susceptibility genes LCE3D and TNIP1 in patients with psoriasis. It can further be used to predict the clinical efficacy and side effects of MTX in the treatment of psoriasis, and help guide clinicians to formulate appropriate MTX treatment intervention programs.

Description

Technical field [0001] The invention belongs to the field of biotechnology, and involves the susceptibility genes of psoriasis and their use thereof. Specific involves the use of psorous susceptibility gene LCE3D and TNIP1 and its use in the preparation of testing test cartridges, the kit is easy to detect patients with psoriasis The SNP site of gene LCE3D and TNIP1, predicts the clinical efficacy and poisonous side effects of MTX. Background technique [0002] The prior art discloses psoriasis as common chronic inflammatory diseases, which can be tired of skin, nail, joint, kidney, cardiovascular, etc. A serious physical and mental damage and economic burden is given to patients. Among the pharmaceutical intervention commonly used in clinical practice, the usual use of the Avi A is only about 20%, and the blood lipid is increased, increasing the risk of cardiovascular disease, and some patients will also damage the liver and renal function; related biological agents Although the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C12Q1/6883
CPCC12Q1/6883C12Q2600/106C12Q2600/172C12Q2600/156
Inventor 颜克香徐金华张学军
Owner AFFILIATED HUSN HOSPITAL OF FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap